Maze Therapeutics, Inc.
MAZE evidence brief
What we can confirm
- BioSniper Score:
- 5.4 / 10
- Market Cap:
- $1.50B
- Lead Asset:
- mze001 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for MAZE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MAZE
Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases, with lead programs in APOL1-mediated kidney disease (MZE829) and phenylketonuria/chronic kidney disease (MZE782).
Key risk: Net loss trend
BioSniper Score
Based on 4 of 6 signals
Market Cap
$1.50B
Cash Runway
—
Lead Asset
mze001 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 2 clinical trials for Maze Therapeutics, Inc..
Similar companies
Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases, with lead programs in APOL1-mediated kidney disease (MZE829) and phenylketonuria/chronic kidney disease (MZE782).
- Cash & equivalents of $202.6M as of 2026-06-30 [sec].
- Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease showed positive topline proof-of-concept data [news · 2026-05-12].
- Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data expected in 2027 [news · 2026-08-11].
- Phase 2 trial of MZE782 in CKD on track for H1 2027 initiation [news · 2026-08-11].
- MZE001 (Pompe disease) is in Phase 1 with partner Shionogi, including a $150M upfront payment [pipeline].
What works
- Positive Phase 2 proof-of-concept data for MZE829 in APOL1-mediated kidney disease supports advancement toward a pivotal trial [news · 2026-05-12].
- Strong balance sheet with $202.6M cash as of 2026-06-30 provides expected runway into 2029 [sec][news · 2026-08-11].
- MZE782 has shown best- and first-in-class potential in Phase 1, with two Phase 2 trials underway or planned [news · 2025-11-07][news · 2026-08-11].
What to weigh
- Net loss of $44.7M as of 2026-06-30 indicates ongoing operating expenses exceed revenue [sec].
- Phase 2 HORIZON data raised questions on upside and risk, per a June 2026 news report [news · 2026-06-13].
- MZE001 faces a competitive landscape with 30 competitors including Sanofi and Genzyme [pipeline].
From the filings
Quoted directly from source documents.
Positive Phase 2 HORIZON data for MZE829
“Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support advancement into pivotal trial”
News · May 12, 2026
MZE782 Phase 2 PKU trial initiated
“Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data expected in 2027”
News · August 11, 2026
MZE001 collaboration with Shionogi
“Upfront payment of $150 million and the potential for additional milestones and royalties.”
Catalyst timeline
- 2025-02-05 · Phase 2 start for MZE829 in APOL1-mediated kidney disease — Open-label Phase 2 study evaluating safety, tolerability, and effect on albuminuria in adults with proteinuric CKD and APOL1 high-risk genotype.
- 2026-06-23 · Phase 2 start for MZE782 in PKU — Randomized, double-blind, placebo-controlled, dose-ranging study evaluating safety, tolerability, and efficacy in adults with PKU.
Risks & what to watch (3)›
Key risks
- Net loss trend — Net loss of $44.7M as of 2026-06-30; ongoing R&D spending may pressure runway [sec].
- Clinical trial uncertainty — Phase 2 HORIZON data raised questions on upside and risk; pivotal trial outcomes unknown [news · 2026-06-13].
- Competitive landscape for MZE001 — 30 competitors in Pompe disease, including Sanofi and Genzyme with later-stage programs [pipeline].
What to watch
- Additional HORIZON data from all cohorts expected in late 2026 or early 2027 [news · 2026-08-11].
- Topline data from Phase 2 CIPheR trial of MZE782 in PKU expected in 2027 [news · 2026-08-11].
- Initiation of Phase 2 trial of MZE782 in CKD expected in H1 2027 [news · 2026-08-11].
- Presentations at ASN Kidney Week 2026 for MZE829 and MZE782 programs [news · 2026-10-06].
Sources: Catalysts · News · Pipeline · Generated October 12, 2026 · How we verify sources →
Run Maze Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Maze Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.17 · 0% dilution
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
0 buys · 28 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
165
Total value held
$1.53B
| Holder | Shares | Value |
|---|---|---|
| frazier life sciences management, l.p. | 4,567,274 | $136.3M |
| trv gp iv, llc | 4,473,958 | $133.5M |
| arch venture management, llc | 4,120,053 | $123.0M |
| deep track capital, lp | 3,477,562 | $103.8M |
| janus henderson group plc | 2,858,876 | $85.3M |
| paradigm biocapital advisors lp | 2,744,399 | $81.9M |
| blackrock, inc. | 2,570,425 | $76.7M |
| a16z capital management, l.l.c. | 1,702,225 | $50.8M |
| venrock adviser, llc | 1,602,034 | $47.8M |
| vanguard capital management llc | 1,435,656 | $42.9M |
Showing top 10 of 165 institutional holders of Maze Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 9.1%
- Days to cover
- 2.8
- Shares short
- 3,795,902
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MAZE short interestGovernance
Frequently asked questions
What is the AI investment thesis for Maze Therapeutics, Inc.?
Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases, with lead programs in APOL1-mediated kidney disease (MZE829) and phenylketonuria/chronic kidney disease (MZE782).
What is Maze Therapeutics, Inc.'s lead drug candidate?
Maze Therapeutics, Inc.'s most advanced tracked candidate is mze001 (Phase 1) for Pompe disease.
Who is the CEO of Maze Therapeutics, Inc.?
Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D. is the chief executive officer of Maze Therapeutics, Inc. (MAZE).
Where is Maze Therapeutics, Inc. headquartered?
Maze Therapeutics, Inc. (MAZE) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does Maze Therapeutics, Inc. focus on?
Maze Therapeutics, Inc. develops therapies across Rare Disease, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.